Harborside


Lexaria Bioscience Corp.

LEXX


Canadian symbol: LEXX
US symbol: LEXX

Currency in USD

Valuation Measures4

Market Cap (intraday) N/A
Enterprise Value N/A
Trailing P/E N/A
Forward P/E N/A
PEG Ratio (5 yr expected) N/A
Price/Sales (ttm)N/A
Price/Book (mrq)N/A
Enterprise Value/Revenue N/A
Enterprise Value/EBITDA N/A

Trading Information

Stock Price History

Beta (5Y Monthly) 1.67
52-Week Change 3N/A
S&P500 52-Week Change 3N/A
52 Week High 312.5000
52 Week Low 33.9750
50-Day Moving Average 36.2257
200-Day Moving Average 36.1484

Share Statistics

Avg Vol (3 month) 3165.92k
Avg Vol (10 day) 372.78k
Shares Outstanding 55.1M
Implied Shares Outstanding 6N/A
Float 82.56M
% Held by Insiders 114.91%
% Held by Institutions 16.29%
Shares Short (Apr. 29, 2021) 4281.12k
Short Ratio (Apr. 29, 2021) 48.8
Short % of Float (Apr. 29, 2021) 46.15%
Short % of Shares Outstanding (Apr. 29, 2021) 45.51%
Shares Short (prior month Mar. 30, 2021) 4294.59k

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 3N/A
Trailing Annual Dividend Yield 3N/A
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3Jan. 11, 2021
Ex-Dividend Date 4N/A
Last Split Factor 2N/A
Last Split Date 3N/A

Financial Highlights

Fiscal Year

Fiscal Year Ends Aug. 30, 2020
Most Recent Quarter (mrq)Feb. 27, 2021

Profitability

Profit Margin 0.00%
Operating Margin (ttm)-473.77%

Management Effectiveness

Return on Assets (ttm)-32.31%
Return on Equity (ttm)-35.13%

Income Statement

Revenue (ttm)772.57k
Revenue Per Share (ttm)0.24
Quarterly Revenue Growth (yoy)411.30%
Gross Profit (ttm)276.93k
EBITDA -3.56M
Net Income Avi to Common (ttm)-2.28M
Diluted EPS (ttm)N/A
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)9.82M
Total Cash Per Share (mrq)1.92
Total Debt (mrq)115.25k
Total Debt/Equity (mrq)0.99
Current Ratio (mrq)27.41
Book Value Per Share (mrq)N/A

Cash Flow Statement

Operating Cash Flow (ttm)-2.96M
Levered Free Cash Flow (ttm)-1.65M

mrq = Most Recent Quarter
ttm = Trailing Twelve Months
yoy = Year Over Year
lfy = Last Fiscal Year
fye = Fiscal Year Ending
fy = Forward Year
Shares outstanding is taken from the most recently filed quarterly or annual report and Market Cap is calculated using shares outstanding.

Fundamentals are updated every day.
Full screen




Cannabis Market and Business News

Real-time cannabis business news from hundreds of sources. Never miss the news that matters the most.




Company News Date
LEXX
Lexaria Bioscience
2 days ago
LEXX
Lexaria Bioscience
1 week ago
LEXX
Lexaria Bioscience
1 month ago
LEXX
Lexaria Bioscience
1 month ago
LEXX
Lexaria Bioscience
1 month ago
LEXX
Lexaria Bioscience
1 month ago
LEXX
Lexaria Bioscience
1 month ago
LEXX
Lexaria Bioscience
2 months ago
LEXX
Lexaria Bioscience
2 months ago
LEXX
Lexaria Bioscience
2 months ago
LEXX
Lexaria Bioscience
3 months ago
LEXX
Lexaria Bioscience
4 months ago
LEXX
Lexaria Bioscience
5 months ago
LEXX
Lexaria Bioscience
6 months ago
LEXX
Lexaria Bioscience
6 months ago
LEXX
Lexaria Bioscience
7 months ago
LEXX
Lexaria Bioscience
7 months ago
LEXX
Lexaria Bioscience
7 months ago
LEXX
Lexaria Bioscience
7 months ago
LEXX
Lexaria Bioscience
8 months ago
LEXX
Lexaria Bioscience
10 months ago
LEXX
Lexaria Bioscience
11 months ago
LEXX
Lexaria Bioscience
1 year ago
LEXX
Lexaria Bioscience
1 year ago
LEXX
Lexaria Bioscience
1 year ago
LEXX
Lexaria Bioscience
1 year ago
LEXX
Lexaria Bioscience
1 year ago
LEXX
Lexaria Bioscience
1 year ago
LEXX
Lexaria Bioscience
1 year ago
LEXX
Lexaria Bioscience
1 year ago
LEXX
Lexaria Bioscience
1 year ago
LEXX
Lexaria Bioscience
1 year ago
LEXX
Lexaria Bioscience
1 year ago
LEXX
Lexaria Bioscience
1 year ago
LEXX
Lexaria Bioscience
1 year ago
LEXX
Lexaria Bioscience
1 year ago
LEXX
Lexaria Bioscience
1 year ago
LEXX
Lexaria Bioscience
1 year ago
LEXX
Lexaria Bioscience
1 year ago
LEXX
Lexaria Bioscience
1 year ago
LEXX
Lexaria Bioscience
1 year ago
LEXX
Lexaria Bioscience
1 year ago
LEXX
Lexaria Bioscience
1 year ago
LEXX
Lexaria Bioscience
1 year ago
LEXX
Lexaria Bioscience
1 year ago
LEXX
Lexaria Bioscience
1 year ago
LEXX
Lexaria Bioscience
1 year ago
LEXX
Lexaria Bioscience
1 year ago
LEXX
Lexaria Bioscience
1 year ago
LEXX
Lexaria Bioscience
1 year ago
LEXX
Lexaria Bioscience
1 year ago
LEXX
Lexaria Bioscience
1 year ago
LEXX
Lexaria Bioscience
2 years ago
LEXX
Lexaria Bioscience
2 years ago
LEXX
Lexaria Bioscience
2 years ago
LEXX
Lexaria Bioscience
2 years ago
LEXX
Lexaria Bioscience
2 years ago
LEXX
Lexaria Bioscience
2 years ago
LEXX
Lexaria Bioscience
2 years ago
LEXX
Lexaria Bioscience
2 years ago
LEXX
Lexaria Bioscience
2 years ago
LEXX
Lexaria Bioscience
2 years ago
LEXX
Lexaria Bioscience
2 years ago
LEXX
Lexaria Bioscience
2 years ago
LEXX
Lexaria Bioscience
2 years ago
LEXX
Lexaria Bioscience
2 years ago
LEXX
Lexaria Bioscience
2 years ago
LEXX
Lexaria Bioscience
2 years ago
LEXX
Lexaria Bioscience
2 years ago
LEXX
Lexaria Bioscience
2 years ago
LEXX
Lexaria Bioscience
2 years ago
LEXX
Lexaria Bioscience
2 years ago
LEXX
Lexaria Bioscience
2 years ago
LEXX
Lexaria Bioscience
2 years ago
LEXX
Lexaria Bioscience
2 years ago
LEXX
Lexaria Bioscience
2 years ago
LEXX
Lexaria Bioscience
2 years ago
LEXX
Lexaria Bioscience
2 years ago
LEXX
Lexaria Bioscience
2 years ago
LEXX
Lexaria Bioscience
2 years ago
LEXX
Lexaria Bioscience
2 years ago
LEXX
Lexaria Bioscience
2 years ago
LEXX
Lexaria Bioscience
2 years ago
LEXX
Lexaria Bioscience
2 years ago
LEXX
Lexaria Bioscience
2 years ago
LEXX
Lexaria Bioscience
2 years ago
LEXX
Lexaria Bioscience
2 years ago
LEXX
Lexaria Bioscience
2 years ago
LEXX
Lexaria Bioscience
2 years ago
LEXX
Lexaria Bioscience
2 years ago

Currency in USD
Earnings EstimateCurrent Qtr.Next Qtr.Current YearNext Year
No. of Analysts0000
Avg. Estimate0000
Low Estimate0000
High Estimate0000
Year Ago EPSN/AN/AN/AN/A
Revenue EstimateCurrent Qtr.Next Qtr.Current YearNext Year
No. of Analysts0000
Avg. EstimateN/AN/AN/AN/A
Low EstimateN/AN/AN/AN/A
High EstimateN/AN/AN/AN/A
Year Ago SalesN/AN/AN/AN/A
Sales Growth (year/est)N/AN/AN/AN/A
Earnings HistoryInvalid DateInvalid DateInvalid DateInvalid Date
EPS Est.N/AN/AN/AN/A
EPS ActualN/AN/AN/AN/A
DifferenceN/AN/AN/AN/A
Surprise %N/AN/AN/AN/A
EPS TrendCurrent Qtr.Next Qtr.Current YearNext Year
Current Estimate0000
7 Days Ago0000
30 Days Ago0000
60 Days Ago0000
90 Days Ago0000
EPS RevisionsCurrent Qtr.Next Qtr.Current YearNext Year
Up Last 7 DaysN/AN/AN/AN/A
Up Last 30 DaysN/AN/AN/AN/A
Down Last 7 DaysN/AN/AN/AN/A
Down Last 30 DaysN/AN/AN/AN/A
Growth EstimatesLEXXIndustrySector(s)S&P 500
Current Qtr.N/AN/AN/AN/A
Next Qtr.N/AN/AN/AN/A
Current YearN/AN/AN/AN/A
Next YearN/AN/AN/AN/A
Next 5 Years (per annum)N/AN/AN/AN/A
Past 5 Years (per annum)N/AN/AN/AN/A


Insiders transactions are updated every hour.

Major Holders

Currency in USD
Breakdown
14.91%% of Shares Held by All Insider
6.29%% of Shares Held by Institutions
7.39%% of Float Held by Institutions
12Number of Institutions Holding Shares

Top Institutional Holders

HolderSharesDate Reported% OutValue
Invenomic Capital Management, LP296,101Mar. 30, 20210.37%1,661,126
Citadel Advisors LLC14,915Mar. 30, 20210.02%83,673
Coming Soon

Search SEDAR Filings

Company Name:
Document Type:
Start Date:
End Date:

Press Releases by Lexaria Bioscience Corp.


Lexaria Bioscience Corp. (NASDAQ: LEXX) Emerging as Leader in Pursuit of More-Effective Hypertension Treatment

Lexaria Bioscience Corp. (NASDAQ: LEXX) Emerging as Leader in Pursuit of More-Effective Hypertension Treatment

NEW YORK, Sept. 16, 2021 -- NetworkNewsAudio – Lexaria Bioscience Corp. (NASDAQ: LEXX) announces the availability of a broadcast titled, “Hypertension: The Silent Killer Making Loud Noise for Investors.” To hear the AudioPressRelease, please visit: The NetworkNewsAudio News Podcast To view the full editorial, please visit: https://nnw.fm/... Read More...
Lexaria Bioscience Corp. (NASDAQ: LEXX) on Forefront of Exciting Hypertension Innovation

Lexaria Bioscience Corp. (NASDAQ: LEXX) on Forefront of Exciting Hypertension Innovation

NEW YORK, Aug. 06, 2021 -- NetworkNewsAudio – Lexaria Bioscience Corp. (NASDAQ: LEXX) announces the availability of a broadcast titled, “Cardiovascular Disease Drug Market Offers Compelling Potential for First Movers, Innovators in the Space.” To hear the AudioPressRelease, please visit: The NetworkNewsAudio News Podcast To view the full ... Read More...
Lexaria Bioscience Corp. (NASDAQ: LEXX) Leads the Way in Innovating Hypertension Treatment

Lexaria Bioscience Corp. (NASDAQ: LEXX) Leads the Way in Innovating Hypertension Treatment

NEW YORK, Aug. 04, 2021 -- via InvestorWire — Lexaria Bioscience Corp. (NASDAQ: LEXX) today announces its placement in an editorial published by NetworkNewsWire ("NNW"), one of 50+ trusted brands within the InvestorBrandNetwork (“IBN”), a multifaceted financial news and publishing company for private and public entities. To view the full ... Read More...
Lexaria Bioscience Corp. Discusses $11 Million Public Offering and 2021 Goals with The Stock Day Podcast

Lexaria Bioscience Corp. Discusses $11 Million Public Offering and 2021 Goals with The Stock Day Podcast

Phoenix, Arizona--(Newsfile Corp. - January 28, 2021) - The Stock Day Podcast welcomed Lexaria Bioscience Corp. (NASDAQ: LEXX) (CSE: LXX) ("the Company"), a company with the proprietary drug delivery technology, DehydraTECH™, which improves the way active pharmaceutical ingredients (APIs) enter the bloodstream. CEO of the Company, Chris B... Read More...
Lexaria Bioscience Corp. Announces Closing of $11 Million Public Offering with Full Exercise of Underwriter Option to Purchase Additional Shares and Warrants

Lexaria Bioscience Corp. Announces Closing of $11 Million Public Offering with Full Exercise of Underwriter Option to Purchase Additional Shares and Warrants

KELOWNA, BC / ACCESSWIRE / January 15, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)(CSE:LXX) (the "Company") today announced the closing of its previously announced underwritten public offering (the "Offering") of 1,828,571 units, each unit consisting of one share of common stock and one warrant to purchase one share of com... Read More...
Lexaria Bioscience Corp. Discusses Demonstration of Improved Oral Delivery for Antiviral Drugs with The Stock Day Podcast

Lexaria Bioscience Corp. Discusses Demonstration of Improved Oral Delivery for Antiviral Drugs with The Stock Day Podcast

Phoenix, Arizona--(Newsfile Corp. - December 8, 2020) - The Stock Day Podcast welcomed Lexaria Bioscience Corp. (OTCQX: LXRP) (CSE: LXX), the developer of DehydraTECH™, a proprietary drug delivery technology that improves the way active pharmaceutical ingredients (APIs) enter the bloodstream. CEO of the Company, Chris Bunka, joined Stock ... Read More...
Lexaria Bioscience Sells Non-Pharmaceutical THC-Related Assets for CDN$3.85M

Lexaria Bioscience Sells Non-Pharmaceutical THC-Related Assets for CDN$3.85M

Asset Sale in Preparation for US National Securities Exchange ListingKELOWNA, BC / ACCESSWIRE / November 19, 2020 / Lexaria Bioscience Corp. (OTCQX:LXRP)(CSE:LXX) (the "Company" or "Lexaria"), a global innovator in oral drug delivery platforms, has entered a definitive asset purchase agreement (the "Agreement"), through its wholly owned s... Read More...
Lexaria Bioscience Extends Warrant Term

Lexaria Bioscience Extends Warrant Term

KELOWNA, BC / ACCESSWIRE / October 26, 2020 / Lexaria Bioscience Corp. (OTCQX:LXRP) (CSE:LXX) (the "Company" or "Lexaria"), a global innovator in oral drug delivery platforms, has determined to extend the term of an aggregate 1,823,745 share purchase warrants (the "Warrants"), which were issued pursuant to a private placement of units.The... Read More...
Lexaria Bioscience Supports Corporate Growth Initiatives by its Licensee, Cannadips CBD by the Boldt Runners Corporation

Lexaria Bioscience Supports Corporate Growth Initiatives by its Licensee, Cannadips CBD by the Boldt Runners Corporation

KELOWNA, BC / ACCESSWIRE / September 16, 2020 / Lexaria Bioscience Corp. (OTCQX:LXRP)(CSE:LXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, proudly supports the corporate growth initiatives underway by its DehydraTECHTM licensee, Boldt Runners Corporation ("Boldt Runners"), owners of the Cannadips CBD bran... Read More...
Lexaria BioScience Receives Ethics Board Approval to Conduct Exploratory Clinical Study using Cannabidiol for Blood Pressure Reduction

Lexaria BioScience Receives Ethics Board Approval to Conduct Exploratory Clinical Study using Cannabidiol for Blood Pressure Reduction

Complements previously published data that cites Lexaria's TurboCBD to demonstrate a significant 5% reduction in mean arterial blood pressure KELOWNA, BC / ACCESSWIRE / July 28, 2020 / Lexaria Bioscience Corp. (OTCQX:LXRP) (CSE:LXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announced that it has received... Read More...
Lexaria Bioscience Applies for NIH Grant for COVID-19 Therapy Studies and Receives New Expanded Health Canada License

Lexaria Bioscience Applies for NIH Grant for COVID-19 Therapy Studies and Receives New Expanded Health Canada License

KELOWNA, BC / ACCESSWIRE / June 18, 2020 / Lexaria Bioscience Corp. (OTCQX:LXRP)(CSE:LXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces it has submitted a grant application to the U.S. National Institutes of Health (NIH) entitled "In vitro and in vivo animal exploratory pharmacokinetic and prelimin... Read More...
Lexaria Bioscience Expands Pharmaceutical Division to Include Lipophilic Antiviral Active Molecules for COVID-19 Treatment

Lexaria Bioscience Expands Pharmaceutical Division to Include Lipophilic Antiviral Active Molecules for COVID-19 Treatment

KELOWNA, BRITISH COLUMBIA / ACCESSWIRE / March 23, 2020 / Lexaria Bioscience Corp. (LXRP)(LXX.CN) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, has expanded the scope and activities of its 100%-owned subsidiary Lexaria Pharmaceutical Corp., to investigate how Lexaria's patented DehydraTECHTM drug delivery te... Read More...
Lexaria Bioscience Begins Coronavirus COVID-19 Drug Delivery Program

Lexaria Bioscience Begins Coronavirus COVID-19 Drug Delivery Program

KELOWNA, BC / ACCESSWIRE / March 19, 2020 / Lexaria Bioscience Corp. (LXRP) (LXX.CN) (the "Company" or "Lexaria"), a global innovator in drug delivery technology, announces it is commencing a program, in collaboration with leading laboratories in Canada and the USA, to study the benefits of Lexaria's DehydraTECHTM drug delivery platform f... Read More...
Industry Solutions from Lexaria's DehydraTECHTM Hemp and Cannabis Powders

Industry Solutions from Lexaria’s DehydraTECHTM Hemp and Cannabis Powders

KELOWNA, BC / ACCESSWIRE / February 13, 2020 / Lexaria Bioscience Corp. (LXRP) (LXX.CN) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces that its DehydraTECHTM-enabled CBD infused powders are now available for sale across the USA to businesses wanting to produce topicals and edibles with clinically p... Read More...
Lexaria Bioscience Corp. and Cannadips Cannabis Announce Expanded Relationship Into Cannabis Oral Pouch & Dip Category

Lexaria Bioscience Corp. and Cannadips Cannabis Announce Expanded Relationship Into Cannabis Oral Pouch & Dip Category

KELOWNA, BC / ACCESSWIRE / January 22, 2020 / Lexaria Bioscience Corp. (LXRP)(LXX.CN) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces that it has reached a new definitive agreement to provide its patented DehydraTECHTM technology to Cannadips' cannabis products, both in its current California market,... Read More...
Lexaria Bioscience Corp. and Cannadips CBD Announce Definitive Technology Licensing agreement for CBD Oral Pouch & Dip Category

Lexaria Bioscience Corp. and Cannadips CBD Announce Definitive Technology Licensing agreement for CBD Oral Pouch & Dip Category

KELOWNA, BC / ACCESSWIRE / January 14, 2020 / Lexaria Bioscience Corp. (LXRP)(LXX.CN) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces that it has reached a definitive agreement to provide its patented DehydraTECHTM technology to Cannadips CBD, the Original Smokeless CBD Dip Brand.Cannadips CBD is Ame... Read More...
Hill Street Sees 300% YOY Increase in Holiday Pack Sales and Provides Operational Update

Hill Street Sees 300% YOY Increase in Holiday Pack Sales and Provides Operational Update

Hill Street's Entertainer Pack at major retailers in time for Christmas and New Year'sToronto, Ontario--(Newsfile Corp. - December 23, 2019) - Hill Street Beverage Company Inc. (TSXV: BEER) ("Hill Street" or the "Company"), is pleased to announce the launch of its new Entertainer's Pack of alcohol-free wines has achieved national distribu... Read More...
Pure Ratios CEO Chad Conner Releases 15-Part Video Series on Cannabis Medicine

Pure Ratios CEO Chad Conner Releases 15-Part Video Series on Cannabis Medicine

Pure Ratios Holdings, a subsidiary of 4Front Ventures Corp. (CSE:FFNT.CN)(OTCQX:FFNTF), continues its mission to educate the public on the science of cannabis with a video series about the endocannabinoid systemSAN DIEGO, CA / ACCESSWIRE / November 27, 2019 / Chad Conner, CEO and co-founder of the San Diego cannabis wellness brand, Pure R... Read More...
Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Featured in NetworkNewsWire Publication Reporting on Momentous Advances in Drug-Delivery Innovation

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Featured in NetworkNewsWire Publication Reporting on Momentous Advances in Drug-Delivery Innovation

NEW YORK, Sept. 05, 2019 -- via NetworkWire — Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) today announces its placement in an editorial published by NetworkNewsWire ("NNW"), a multifaceted financial news and publishing company for private and public entities.To view the full publication, titled “Innovative Drug-Delivery Sy... Read More...
Lexaria Bioscience Announces DehydraTECH Patent for Pharmaceutical Applications of Cannabinoids to Treat Certain Disease Conditions

Lexaria Bioscience Announces DehydraTECH Patent for Pharmaceutical Applications of Cannabinoids to Treat Certain Disease Conditions

Lexaria Bioscience Corp. CONNECT TO Lexaria Bioscience Corp. Tuesday, August 27, 2019 6:15 AM KELOWNA, BC / ACCESSWIRE / August 27, 2019 / Lexaria Bioscience Corp. (OTCQX:LXRP) (CSE:LXX) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, is pleased to an... Read More...
Lexaria Announces Commercial Launch of ChrgD+ Odorless, Flavorless, Water-Soluble Powdered Hemp Oil

Lexaria Announces Commercial Launch of ChrgD+ Odorless, Flavorless, Water-Soluble Powdered Hemp Oil

KELOWNA, BC / ACCESSWIRE / August 22, 2019 / Lexaria Bioscience Corp. (LXRP) (LXX.CN) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, is pleased to announce the online commercial launch of ChrgD+, the industry’s most advanced water-soluble multi-spectrum hemp oil in a powdered format and empowered with Dehydra... Read More...
Lexaria's Appoints Former Altria Group Senior Executive and Operating Company Chief to Board of Directors

Lexaria’s Appoints Former Altria Group Senior Executive and Operating Company Chief to Board of Directors

KELOWNA, BC / ACCESSWIRE / August 14, 2019 / Lexaria Bioscience Corp. (LXRP) (LXX.CN) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, is pleased to announce the appointment of Mr. Brian Quigley to its board of directors. Mr. Quigley most recently spent 16 years at Altria Group, with 7 of those years spent as P... Read More...
Lexaria Bioscience Completes Initial Project with Canada’s National Research Council

Lexaria Bioscience Completes Initial Project with Canada’s National Research Council

No chemical modification or degradation of Active Pharmaceutical Ingredients evidenced using DehydraTECH after acidic pH stability testingStrategically significant absence of covalent-bonded New Molecular Entity creation using DehydraTECHKELOWNA, BC / ACCESSWIRE / August 8, 2019 / Lexaria Bioscience Corp. (LXRP) (LXX.CN), (the “Company” o... Read More...
Lexaria Bioscience Engages Integra Consulting Group to Provide Investor Relations Services

Lexaria Bioscience Engages Integra Consulting Group to Provide Investor Relations Services

KELOWNA, BC / ACCESSWIRE / August 2, 2019 / Lexaria Bioscience Corp. (LXX.CN) (LXRP) (“Lexaria” or the “Company”) announces it has retained Integra Consulting Group LLC (“Integra”) to provide investor relations services to the Company in compliance with regulatory guidelines.Integra partners with select underexposed and undervalued emergi... Read More...
Lexaria Bioscience Corp. Featured in CannabisNewsAudio Broadcast on Dramatic Results of CBD Delivery System Study

Lexaria Bioscience Corp. Featured in CannabisNewsAudio Broadcast on Dramatic Results of CBD Delivery System Study

NEW YORK, June 13, 2019 -- via CannabisNewsAudio – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) today announces the availability of an audio press release titled, “Dramatically Improved Delivery Systems Promise More Effective Cannabis Treatments.”To hear the CannabisNewsAudio version, visit: http://cnw.fm/My9kX.To read the full edito... Read More...
Lexaria Bioscience Corp. Featured in CannabisNewsAudio Broadcast Touting Impact of Technology on CBD Edible Space

Lexaria Bioscience Corp. Featured in CannabisNewsAudio Broadcast Touting Impact of Technology on CBD Edible Space

NEW YORK, May 31, 2019 -- via CannabisNewsAudio – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) today announces the availability of a CannabisNewsAudio Broadcast titled, “Disruptive CBD Delivery Technology Could Revolutionize World of Cannabis Consumer Products, Edibles.”To hear the CannabisNewsAudio version, visit: http://cnw.fm/xJB7... Read More...
Combining Lexaria's DehydraTECHTM with Nanotech Delivers Increased Quantities of CBD into Brain Tissue

Combining Lexaria’s DehydraTECHTM with Nanotech Delivers Increased Quantities of CBD into Brain Tissue

Lexaria's Patented DehydraTECH Combined with Nanoemulsion Formulation Delivers 1,137% More CBD KELOWNA, BC / ACCESSWIRE / May 28, 2019 / Lexaria Bioscience Corp. (LXRP) (LXX.CN) (the "Company" or "Lexaria"), a drug delivery platform innovator, announces recent animal testing proves that combining Lexaria's DehydraTECHTM delivery technolog... Read More...
Lexaria's DehydraTECH Formulation Delivers 475% More CBD to Bloodstream after 15 Minutes than Conventional Industry Formulations

Lexaria’s DehydraTECH Formulation Delivers 475% More CBD to Bloodstream after 15 Minutes than Conventional Industry Formulations

The DehydraTECH formulation delivered measurable quantities of cannabidiol ("CBD") into blood in as little as 2 minutes;Lexaria's technology delivered more CBD to bloodstream in 15 minutes than conventional medium chain triglyceride ("MCT") oil based control formulation achieved in 60 minutes;The area under the curve ("AUC") for Lexaria's... Read More...
Coming Soon.

Delayed data (1h)


Share this page